References

Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM

10.1126/science.aaw8250 · 2019 · External reference

The AMPA receptor code of synaptic plasticity

10.1016/j.neuron.2018.10.018 · 2018 · External reference

Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death

10.1016/j.tins.2007.01.006 · 2007 · External reference

Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert

10.1016/j.neuron.2018.05.018 · 2018 · External reference

Structural mechanisms of activation and desensitization in neurotransmitter-gated ion channels

10.1038/nsmb.3214 · 2016 · External reference

Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels

10.1124/pharmrev.120.000131 · 2021 · External reference

Flip and flop: a molecular determinant for AMPA receptor channel opening

10.1021/bi8015907 · 2009 · External reference

Glutamate receptors as regulators of synaptic plasticity in neuropsychiatric disorders: pathological insight and translational perspectives

10.1007/s11571-026-10446-y · 2026 · External reference

Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today

10.1016/j.pbb.2025.173967 · 2025 · External reference

Randomized phase III study 306

10.1212/wnl.0b013e318254473a · 2012 · External reference

AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans

10.1097/00000542-199811000-00005 · 1998 · External reference

Positive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Modulators Have Different Impact on Synaptic Transmission in the Thalamus and Hippocampus

10.1124/jpet.104.078196 · 2005 · External reference

AMPA receptor modulators have different impact on hippocampal pyramidal cells and interneurons

10.1016/j.neuroscience.2005.06.031 · 2005 · External reference

Recovery from AMPA Receptor Potentiation by Ampakines

10.3390/futurepharmacol5020027 · 2025 · External reference

The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization

10.1016/s0006-8993(98)00446-6 · 1998 · External reference

High Impact AMPAkines Induce a Gq-Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines

10.1002/syn.22310 · 2024 · External reference

Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574

10.1124/jpet.113.204735 · 2013 · External reference

Pharmacology of Ampakine Modulators: From AMPA Receptors to Synapses and Behavior

10.2174/138945007780618490 · 2007 · External reference

Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents

10.1093/toxsci/kfx277 · 2018 · External reference

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement

2021 · External reference

Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus

10.1016/j.neuroscience.2003.10.033 · 2004 · External reference

A profile of the behavioral changes produced by facilitation of AMPA-type glutamate receptors

10.1007/s002130050386 · 1997 · External reference

The CaMKII/NMDA receptor complex controls hippocampal synaptic transmission by kinase-dependent and independent mechanisms

10.1038/s41467-018-04439-7 · 2018 · External reference

Positive AMPA Receptor Modulation Rapidly Stimulates BDNF Release and Increases Dendritic mRNA Translation

10.1523/jneurosci.6078-08.2009 · 2009 · External reference

Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain

10.1016/j.biopha.2018.06.008 · 2018 · External reference

Form follows function: BDNF and its involvement in sculpting the function and structure of synapses

10.1016/j.neuropharm.2013.05.029 · 2014 · External reference

Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus

10.1523/jneurosci.4037-06.2007 · 2007 · External reference

DRUG FOCUS: S 18986: a positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer

10.1111/j.1755-5949.2009.00088.x · 2010 · External reference

Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity

10.1523/jneurosci.18-07-02748.1998 · 1998 · External reference

Facilitation of olfactory learning by a modulator of AMPA receptors

10.1523/jneurosci.15-12-08023.1995 · 1995 · External reference

Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat

10.1007/s00213-008-1325-2 · 2009 · External reference

Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats

10.1016/s0006-8993(96)01049-9 · 1996 · External reference

Enhancement by an ampakine of memory encoding in humans

10.1006/exnr.1997.6581 · 1997 · External reference

Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans

10.1006/exnr.1997.6447 · 1997 · External reference

Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers

10.1038/sj.npp.1301257 · 2007 · External reference

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial

10.1089/cap.2006.16.525 · 2006 · External reference

AMPA potentiator treatment of cognitive deficits in Alzheimer disease

10.1212/01.wnl.0000260240.46070.7c · 2007 · External reference

Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD - A phase 2A clinical trial

10.1016/j.ejphar.2025.178047 · 2025 · External reference

Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers

10.1002/cpdd.1475 · 2025 · External reference

Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents

10.3390/futurepharmacol4010012 · 2024 · External reference

Acute ampakines increase voiding function and coordination in a rat model of SCI

10.7554/elife.89767 · 2024 · External reference

Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers

10.1038/s41398-022-02148-w · 2022 · External reference

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

10.1177/0269881112458728 · 2012 · External reference

Synaptic failure and α-synuclein

10.1002/mds.26479 · 2016 · External reference

Targeting synapse function and loss for treatment of neurodegenerative diseases

10.1038/s41573-023-00823-1 · 2024 · External reference

Pathophysiological and diagnostic implications of cortical dysfunction in ALS

10.1038/nrneurol.2016.140 · 2016 · External reference

Excitatory amino acids as a final common pathway for neurologic disorders

10.1056/nejm199403033300907 · 1994 · External reference

Amyloid-β–induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks

10.1038/nn.2583 · 2010 · External reference

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia

10.1007/s00401-010-0711-0 · 2010 · External reference

Alzheimer’s Disease Is a Synaptic Failure

10.1126/science.1074069 · 2002 · External reference

The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis

10.1016/j.bbadis.2006.05.002 · 2006 · External reference

Parkinson’s disease: convergence on synaptic homeostasis

10.15252/embj.201898960 · 2018 · External reference

Amyotrophic lateral sclerosis

10.1016/s0140-6736(10)61156-7 · 2011 · External reference

The intersection of amyloid beta and tau at synapses in Alzheimer’s disease

10.1016/j.neuron.2014.05.004 · 2014 · External reference

Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria

10.1016/s1474-4422(07)70178-3 · 2007 · External reference

Soluble Aβ Oligomers Impair Hippocampal LTP by Disrupting Glutamatergic/GABAergic Balance

10.1016/j.nbd.2015.10.019 · 2016 · External reference

Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake

10.1016/j.neuron.2009.05.012 · 2009 · External reference

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

10.1038/nrn2911 · 2010 · External reference

Amyloid-β Induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of Alzheimer’s disease

10.3233/jad-170879 · 2018 · External reference

Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors

10.1371/journal.pone.0184429 · 2017 · External reference

The AMPA receptor positive allosteric modulator S 47445 rescues in vivo CA3-CA1 long-term potentiation and structural synaptic changes in old mice

10.1016/j.neuropharm.2017.06.009 · 2017 · External reference

Upregulation of neurotrophins by S 47445, a novel positive allosteric modulator of AMPA receptors in aged rats

10.1016/j.phrs.2017.04.019 · 2017 · External reference

S 47445 Produces antidepressant- and anxiolytic-like effects through neurogenesis dependent and independent mechanisms

10.3389/fphar.2017.00462 · 2017 · External reference

Anti-GluA3 autoantibodies define a new sub-population of frontotemporal lobar degeneration patients with distinct neuropathological features

10.1016/j.bbi.2024.03.018 · 2024 · External reference

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer’s disease and depressive symptoms

10.1016/j.trci.2019.04.002 · 2019 · External reference

CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer’s disease

2018 · External reference

Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease

10.1017/s1041610212002141 · 2013 · External reference

Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action

10.1124/jpet.102.040360 · 2002 · External reference

Positive Modulation of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid-Type Glutamate Receptors Elicits Neuroprotection after Trimethyltin Exposure in Hippocampus

10.1006/taap.2002.9534 · 2002 · External reference

Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation

10.1016/j.expneurol.2008.07.010 · 2008 · External reference

CX-516 Cortex pharmaceuticals

2002 · External reference

Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report

10.1007/s12031-002-0032-4 · 2002 · External reference

Cognitive impairment in early-stage non-demented Parkinson’s disease patients

10.1111/ane.12189 · 2014 · External reference

MDS clinical diagnostic criteria for Parkinson’s disease

10.1002/mds.26424 · 2015 · External reference

Parkinson’s disease

10.1016/s0140-6736(14)61393-3 · 2015 · External reference

Early diagnosis and therapy of Parkinson’s disease: can disease progression be curbed?

10.1007/s00702-012-0840-9 · 2013 · External reference

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways

10.1038/nn835 · 2002 · External reference

Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons

10.1113/jphysiol.2006.105510 · 2006 · External reference

Treatment of Parkinson’s disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport

10.3389/fnagi.2023.1276376 · 2023 · External reference

Brain-derived neurotrophic factor and nerve growth factor therapeutics for brain injury: the current translational challenges in preclinical and clinical research

10.1155/2022/3889300 · 2022 · External reference

Targeting glutamatergic synapses in Parkinson’s disease

10.1016/j.coph.2014.10.011 · 2015 · External reference

Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro

10.1016/s0028-3908(01)00040-5 · 2001 · External reference

Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo

10.1016/s0028-3908(01)00031-4 · 2001 · External reference

LY404187, a potentiator of AMPARs, enhances both the amplitude and 1/CV2 of AMPA EPSCs but not NMDA EPSCs at CA3–CA1 synapses in the hippocampus of neonatal rats

10.1016/j.neulet.2012.10.020 · 2012 · External reference

An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study

10.1016/s0028-3908(02)00066-7 · 2002 · External reference

Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro

10.1016/s0028-3908(01)00027-2 · 2001 · External reference

Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson’s disease

10.1016/j.ejphar.2003.12.023 · 2004 · External reference

LY503430: Pharmacology, Pharmacokinetics, and Effects in Rodent Models of Parkinson’s Disease

10.1111/j.1527-3458.2005.tb00037.x · 2005 · External reference

LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson’s Disease

10.1124/jpet.103.049445 · 2003 · External reference

Pharmacological Characterization of cGMP Regulation by the Biarylpropylsulfonamide Class of Positive, Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors

10.1124/jpet.106.105734 · 2006 · External reference

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

10.1212/wnl.54.8.1589 · 2000 · External reference

Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy

10.1016/j.pharmthera.2024.108744 · 2025 · External reference

BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices

10.1016/j.neuropharm.2009.01.015 · 2009 · External reference

Ampakine CX614 increases respiratory rate in a mouse model of Parkinson’s disease

10.1016/j.brainres.2023.148448 · 2023 · External reference

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes

10.1016/0092-8674(93)90585-e · 1993 · External reference

Huntington disease

2015 · External reference

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease

10.1038/ng0893-398 · 1993 · External reference

Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington’s disease

10.1093/hmg/ddl224 · 2006 · External reference

Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington’s disease mutation

10.1523/jneurosci.20-13-05115.2000 · 2000 · External reference

Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules

10.1016/j.cell.2004.06.018 · 2004 · External reference

Brain-derived neurotrophic factor in Huntington disease

10.1016/s0006-8993(00)02237-x · 2000 · External reference

Modulation of AMPA receptor surface diffusion restores hippocampal plasticity and memory in Huntington’s disease models

10.1038/s41467-018-06675-3 · 2018 · External reference

Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice

10.1073/pnas.0811228106 · 2009 · External reference

Brief ampakine treatments slow the progression of Huntington’s disease phenotypes in R6/2 mice

10.1016/j.nbd.2010.10.015 · 2011 · External reference

Glutamate excitotoxicity in a model of multiple sclerosis

10.1038/71555 · 2000 · External reference

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

10.1016/s0140-6736(16)31320-4 · 2017 · External reference

Positive allosteric modulation of AMPA receptors via PF4778574 leads to reduced demyelination and clinical disability in experimental models of multiple sclerosis

10.3389/fimmu.2025.1532877 · 2025 · External reference

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

10.1038/13810 · 1999 · External reference

Rett syndrome: insights into genetic, molecular and circuit mechanisms

10.1038/s41583-018-0006-3 · 2018 · External reference

Stereotypical hand movements in 144 subjects with Rett syndrome from the population-based Australian database

10.1002/mds.22851 · 2010 · External reference

Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations

10.1111/pcn.13299 · 2021 · External reference

Early socio-communicative forms and functions in typical Rett syndrome

10.1016/j.ridd.2013.06.040 · 2013 · External reference

The relationship of Rett syndrome and MECP2 disorders to autism

10.31887/dcns.2012.14.3/jneul · 2012 · External reference

The course of awake breathing disturbances across the lifespan in Rett syndrome

10.1016/j.braindev.2018.03.010 · 2018 · External reference

Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks

10.1002/cne.22009 · 2009 · External reference

Mechanisms of Functional Hypoconnectivity in the Medial Prefrontal Cortex of Mecp2 Null Mice

10.1093/cercor/bhv002 · 2016 · External reference

Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome

10.1073/pnas.0506071102 · 2005 · External reference

Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2

10.1016/j.expneurol.2009.05.001 · 2009 · External reference

Ampakine CX546 increases proliferation and neuronal differentiation in subventricular zone stem/progenitor cell cultures

10.1111/j.1460-9568.2012.08072.x · 2012 · External reference

Brain-Derived Neurotrophic Factor Expression and Respiratory Function Improve after Ampakine Treatment in a Mouse Model of Rett Syndrome

10.1523/jneurosci.1869-07.2007 · 2007 · External reference

The enhancement of activity rescues the establishment of Mecp2 null neuronal phenotypes

10.15252/emmm.202012433 · 2021 · External reference

Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey

10.1002/ajmg.a.32439 · 2008 · External reference

Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors

10.1002/ajmg.a.30229 · 2004 · External reference

Cognitive profiles of boys with the fragile X syndrome

10.1002/ajmg.1320300118 · 1988 · External reference

Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox

10.1016/0092-8674(91)90283-5 · 1991 · External reference

Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers

10.1093/hmg/10.14.1449 · 2001 · External reference

Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons

10.1111/j.1601-183x.2005.00128.x · 2005 · External reference

FMR1 Protein: Conserved RNP Family Domains and Selective RNA Binding

10.1126/science.7692601 · 1993 · External reference

FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism

10.1016/j.cell.2011.06.013 · 2011 · External reference

Rescue of NMDAR-Dependent Synaptic Plasticity in Fmr1 Knock-Out Mice

10.1093/cercor/bht237 · 2015 · External reference

Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression

10.1016/j.neuron.2006.07.005 · 2006 · External reference

WT. Dendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome

10.1093/cercor/10.10.1038 · 2000 · External reference

Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome

10.1016/j.neuron.2005.07.005 · 2005 · External reference

Brain-Derived Neurotrophic Factor Rescues Synaptic Plasticity in a Mouse Model of Fragile X Syndrome

10.1523/jneurosci.2624-07.2007 · 2007 · External reference

A TrkB agonist and ampakine rescue synaptic plasticity and multiple forms of memory in a mouse model of intellectual disability

10.1016/j.nbd.2019.104604 · 2020 · External reference

AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

10.1038/s41467-019-10910-w · 2019 · External reference

Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes

10.1093/brain/awad403 · 2024 · External reference

De Novo Variants in GRIA4 Lead to Intellectual Disability with or without Seizures and Gait Abnormalities

10.1016/j.ajhg.2017.11.004 · 2017 · External reference

Unraveling GRIA1 neurodevelopmental disorders: Lessons learned from the p.(Ala636Thr) variant

10.1111/cge.14577 · 2024 · External reference

Calcium-Permeable AMPA Receptors in the Nucleus Accumbens Regulate Depression-Like Behaviors in the Chronic Neuropathic Pain State

10.1523/jneurosci.2454-13.2013 · 2013 · External reference

Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving

10.1038/nature06995 · 2008 · External reference

Discovery of GluA3 preferring AMPA receptor positive allosteric modulator

2026 · External reference

Glutamate-operated channels: Developmentally early and mature forms arise by alternative splicing

10.1016/0896-6273(91)90176-z · 1991 · External reference

Alternative Splicing of the Flip/Flop Cassette and TARP Auxiliary Subunits Engage in a Privileged Relationship That Fine-Tunes AMPA Receptor Gating

10.1523/jneurosci.2293-22.2023 · 2023 · External reference

Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins

10.1083/jcb.200212116 · 2003 · External reference

Modulation of TARP γ8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain

10.1124/jpet.118.250126 · 2019 · External reference

A first in disease trial of the safety, tolerability, and anti-seizure effects of ES-481 in drug-resistant epilepsy

10.1002/epi4.70294 · 2026 · External reference

Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation

10.1038/s41398-021-01451-2 · 2021 · External reference

Pharmacological MRI: utility in understanding drug mechanisms in psychiatric disorders

10.1002/jmri.70160 · 2026 · External reference

Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders

10.1001/jamapsychiatry.2017.3572 · 2018 · External reference

Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

10.1016/s1474-4422(23)00109-6 · 2023 · External reference

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging

10.1001/jamaneurol.2018.1836 · 2018 · External reference

Visualization of AMPA receptors in living human brain with positron emission tomography

10.1038/s41591-019-0723-9 · 2020 · External reference

Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy

2023 · External reference

Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography

10.1038/s41380-024-02785-1 · 2025 · External reference

The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression

10.1038/s41380-026-03510-w · 2026 · External reference

Modafinil combined with cognitive training is associated with improved learning in healthy volunteers--a randomised controlled trial

10.1016/j.euroneuro.2014.01.001 · 2014 · External reference

NADPH oxidase-1 suppression prolongs the antidepressant-like effect of ketamine

10.1038/s41380-026-03527-1 · 2026 · External reference